- Home
- HRMY vs LMB Comparison
HRMY vs LMB Comparison
Compare HRMY & LMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- LMB
- Stock Information
- Founded
- HRMY 2017
- LMB 1901
- Country
- HRMY United States
- LMB United States
- Employees
- HRMY N/A
- LMB N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- LMB Engineering & Construction
- Sector
- HRMY Health Care
- LMB Consumer Discretionary
- Exchange
- HRMY Nasdaq
- LMB Nasdaq
- Market Cap
- HRMY 1.8B
- LMB 1.6B
- IPO Year
- HRMY 2020
- LMB 2014
- Fundamental
- Price
- HRMY $34.00
- LMB $148.90
- Analyst Decision
- HRMY Strong Buy
- LMB Strong Buy
- Analyst Count
- HRMY 9
- LMB 3
- Target Price
- HRMY $54.44
- LMB $140.67
- AVG Volume (30 Days)
- HRMY 642.5K
- LMB 183.7K
- Earning Date
- HRMY 08-05-2025
- LMB 08-05-2025
- Dividend Yield
- HRMY N/A
- LMB N/A
- EPS Growth
- HRMY 13.13
- LMB 31.50
- EPS
- HRMY 2.62
- LMB 2.78
- Revenue
- HRMY $744,852,000.00
- LMB $532,913,000.00
- Revenue This Year
- HRMY $20.10
- LMB $22.19
- Revenue Next Year
- HRMY $18.01
- LMB $8.71
- P/E Ratio
- HRMY $13.10
- LMB $53.79
- Revenue Growth
- HRMY 20.62
- LMB 3.62
- 52 Week Low
- HRMY $26.47
- LMB $48.17
- 52 Week High
- HRMY $41.61
- LMB $154.05
- Technical
- Relative Strength Index (RSI)
- HRMY 58.91
- LMB 62.85
- Support Level
- HRMY $31.70
- LMB $141.92
- Resistance Level
- HRMY $35.08
- LMB $154.05
- Average True Range (ATR)
- HRMY 0.95
- LMB 6.07
- MACD
- HRMY 0.27
- LMB -0.02
- Stochastic Oscillator
- HRMY 71.80
- LMB 75.93
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About LMB Limbach Holdings Inc.
Limbach Holdings Inc is a commercial specialty contractor in the fields of heating, ventilation, air conditioning, plumbing, electrical, and building controls for the design and construction of new and renovated buildings, maintenance services, energy retrofits, and equipment upgrades. It operates in two segments namely General Contractor Relationships (GCR) and Owner Direct Relationships (ODR). The company generates maximum revenue from the ODR segment.